Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 232 | 232 | 232 |
Full Text Views | 9 | 9 | 9 |
PDF Downloads | 9 | 9 | 9 |
Aerosolized pentamidine is Food and Drug Administration approved to treat Pneumocystis pneumonia via a route that does not lead to systemic absorption or toxicity. Because Leishmania is also susceptible to pentamidine and mucosal leishmaniasis is also an infection of the respiratory tract, we performed a pilot study of aerosolized pentamidine (300 mg for 10 days over approximately 4 weeks) for mucosal leishmaniasis caused by Bolivian Leishmania braziliensis with a 2-year follow-up. Of 15 patients, 6 of 7 patients with initially mild disease were cured, 3 of 4 patients with initially moderate disease relapsed at the 18- to 24-month follow-up visits, and 3 of 4 patients with initially severe disease failed early after treatment. This study suggests that inhaled pentamidine may be useful as a well-tolerated treatment of mild mucosal leishmaniasis and that to rule out relapse, mucosal leishmaniasis follow-up should extend to 2 years.
Financial support: This work was supported by a grant from the
Disclosures: J. Berman is an officer of the AB Foundation, the granting agency for this work. The protocol was approved by the Comite de Bioetica de la Facultad de Medicina, Universidad Mayor de San Simon, Cochabamba, Bolivia.
Current contact information: Jaime Soto and Patricia Gutiérrez, Fundación Nacional de Dermatología y Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia, E-mails: jaime.soto@infoleis.com and pgutierrezduenas@gmail.com. Paula Soto, Fundación Nacional Dermatología, Santa Cruz, Bolivia, E-mail: dra.paula.dermalaser@gmail.com. Julio Escobar, ENT Service, Clínica Foianini, Santa Cruz, Bolivia. David Paz, Daniela Rivero, and Aracely Villalba, Hospital Dermatológico de Jorochito, Santa Cruz, Bolivia, E-mails: davidpazmendoza@hotmail.com, p_d_rivero@hotmail.com, and chelycita83@gmail.com. Jonathan Berman, AB Foundation, North Bethesda, MD, E-mail: jberman@fasttrackresearch.com.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 232 | 232 | 232 |
Full Text Views | 9 | 9 | 9 |
PDF Downloads | 9 | 9 | 9 |